Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 2 |
2020 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.
Exp Cell Res. 2020 Nov 1;396(1):112275. doi: 10.1016/j.yexcr.2020.112275. Epub 2020 Sep 6.
Exp Cell Res. 2020.
PMID: 32898554
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma.
Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K.
Fu Y, et al. Among authors: rathod d.
Pharmaceutics. 2019 Oct 1;11(10):504. doi: 10.3390/pharmaceutics11100504.
Pharmaceutics. 2019.
PMID: 31581483
Free PMC article.
Item in Clipboard
BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation.
Rathod D, Fu Y, Patel K.
Rathod D, et al.
Eur J Pharm Sci. 2019 Oct 1;138:105039. doi: 10.1016/j.ejps.2019.105039. Epub 2019 Aug 5.
Eur J Pharm Sci. 2019.
PMID: 31394259
Item in Clipboard
Cite
Cite